Daiichi Sankyo submits sNDA for WelChol

15 January 2007

Japanese drug major Daiichi Sankyo has filed a supplemental New Drug Application with the US Food and Drug Administration for WelChol (colesevelam HCl) as a drug to improve glycemic control in patients with type 2 diabetes. If approved, the agent will be the first cholesterol-lowering medication also cleared for this indication. Clinical studies have shown that WelChol lowers HbA1C in these patients. A study presented at the American Heart Association's 2006 meeting, showed that WelChol plus insulin demonstrated a mean HbA1C reduction of 0.5% compared to placebo (-0.41% versus +0.09%, p<0.007).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight